How do systemic lupus erythematosus patients with very-long disease duration present? Analysis of a monocentric cohort

• Published in: Lupus 2021-03, Vol.30 (3), p.439-447
• Main Authors: Signorini, Viola, Tani, Chiara, Elefante, Elena, Carli, Linda, Stagnaro, Chiara, Zucchi, Dina, Parma, Alice, Vagelli, Roberta, Ferro, Francesco, Mosca, Marta
• Format: Article
• Language: English
• Subjects: Diagnosis; Hospitalization; Lupus; Patients; Quality of life; Remission; Systemic lupus erythematosus
• ISSN: 0961-2033; 1477-0962
• DOI: 10.1177/0961203320984230

Objective to describe the disease path and the very long-term outcome in a monocentric cohort of patients with Systemic Lupus Erythematosus (SLE). Methods SLE patients with a disease duration of at least 15 years from diagnosis were enrolled. The number of hospitalizations, the disease flares occurred over the disease course and the organ damage accumulation were evaluated at 1, 2, 3, 4, 5, 10 years from diagnosis and at last observation in 2019 as well. Disease state, ongoing therapies and quality of life measures were also assessed at last visit. Results 126 Caucasian SLE patients were included in the analysis (95% female, median age 47.5 IQR 41–53, median disease duration 21 IQR19-26). At last visit, the majority of the patients (78.6%) was on LLDAS (remission included), 53.4% were on GC treatment and 35.7% on immunosuppressant. Furthermore, 53.2% had at least one organ damage. The majority of patients (66.7%) presented a relapsing-remitting course, for a total of 158 flares during the disease course (incidence rate: 0.79/patient-year); moreover, 84.9% of the cohort experienced at least one hospital admission, amounting to a total of 328 hospitalizations (incidence rate: 0.85/patient-year). The main reason for admission was disease activity, while the percentage of hospitalizations due to other causes has been growing over the 10 years of follow-up. Conclusion after a very long period of disease, most of the patients with SLE are in remission and are not taking GC therapy; however, the risk of incurring in disease flare remains a real problem.